Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
With
Washington University School of Medicine
Numbers of T-cell subtypes at six time points in patients with newly diagnosed HGGs undergoing standard RT/TMZ and adjuvant TMZ:
1. Baseline within 2 weeks before initiation of RT/TMZ
2. At the end of RT/TMZ approximately week 6
3. Before adjuvant TMZ approximately week 10
4. After 2 cycle of TMZ approximately week 18
5. After 4 cycle of TMZ approximately week 26
6. Three month after last cycle of TMZ
Secondary Endpoints
1. Changes in serial T cell subtypes and cytokines levels
2. Incidence of lymphopenia related infections
3. Changes in T-cell numbers and subtypes with TMZ administration
4. Overall survival
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients must be at least 18 years of age.
2. Patients must have histologically confirmed new diagnosed high grade glioma by pathology (WHO grade III and IV).
3. Patients proposed post-operative treatment plan must include standard radiation and temozolomide.
4. Patients must have a Karnofsky performance status ≥ 60% (i.e. the patient must be able to care for himself/herself with occasional help from others).
5. Patients must be able to provide written informed consent.
